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Background: Leigh syndrome (LS) is the most common pediatric mitochondrial
diseases caused by MRC defect. LS patients typically have onset age before 2 years
old and have various clinical features. The purpose of this study was to evaluate the
various characteristics between the group that were early onset and late onset patients.
Methods: The medical records of this study used records between 2006 and 2017
(N = 110). Clinical characteristics, diagnostic evaluations, and neuro image studying of
LS were reviewed in our study. We statistically analyzed data from patients diagnosed
with LS at our hospital by using subgroup analysis was performed to divide patients
according to the onset age.
Results: Among the patients, 89 patients (80.9%) had the onset age before 2 years
old, and 21 patents (19.1%) had onset age after 2 years old. In subgroup analysis
first clinical presentation age, diagnosis age and several onset symptoms in the clinical
characteristics were statistically significant. Early onset age group showed delayed
development and late onset age group showed motor weakness and ataxia. However,
Diagnostics evaluation and MRI findings showed no significant differences. The clinical
status monitored during the last visit showed statistically significant differences in the
clinical severity. In the early onset age group clinical status was more severe than late
onset age group.
Conclusions: Although the onset of Leigh syndrome is known to be under 2 years, there
aremany late onset cases were existedmore than expected. Early onset LS patients have
poor prognosis compare with late onset LS patients. Therefore, the specific phenotype
according to the age of onset should be well-observed. Onset of LS is important in
predicting clinical severity or prognosis, and it is necessary to provide individualized
treatment or follow-up protocols for each patient.
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INTRODUCTION
Leigh syndrome (LS) is an early-onset progressive neurodegenerative disease representing the most
common pediatric clinical presentation of mitochondrial disease (1–3). LS was named after Denis
Leigh, the first man to describe this rare neuropathology of infants and young children, which
caused death in the affected patients. LS is known to affect about 1 in 40,000 births (4–7).
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Although LS is associated with considerable clinical and
genetic heterogeneity, the characteristic neuropathological
features are remarkably consistent. Patients with LS most
commonly manifest a progressive decline of central nervous
system function due to focal, necrotizing lesions of the basal
ganglia, diencephalon, cerebellum, or brainstem (5). The clinical
hallmarks of LS include psychomotor delay or regression,
weakness, hypotonia, truncal ataxia, intention tremor, and
lactosidosis of the blood, cerebrospinal fluid (CSF), or urine (8).
The clinical manifestations of LS usually persist for up to
2 years after the initial development. LS patients are typically
described to have the onset time before 2 years of age along with
various clinical features. The disease course is associated with
episodic neurodegeneration, often terminating with death at the
age of 3 years (4, 6, 7, 9–11). Although adult-onset LS has been
reported, it is very rare (12, 13). The purpose of this study was to
evaluate the clinical features, and laboratory and image findings




This study was a retrospective analysis of patients diagnosed
with LS and followed up at Gangnam Severance Hospital
from January 2006 to January 2017. Patients who fulfilled
the following criteria: (1) progressive neurological disease
with motor and intellectual developmental delay; (2) signs
and symptoms of brainstem and/or basal ganglia disease;
(3) raised lactate levels in the blood and/or CSF, and (4)
one or more of the following: (a) characteristic features of
LS on neuroradioimaging [symmetrical hypodensities in the
basal ganglia on computed tomography (CT) or hyperintense
lesions on T2-weighted magnetic resonance imaging (MRI)], (b)
typical neuropathological changes postmortem, or (c) typical
neuropathology in a similarly affected sibling (14) were included.
The Institutional Review Board of Gangnam Severance
Hospital in Seoul, Korea approved all our procedures. Informed
consent was obtained from the parents, and all methods were
performed in accordance with relevant guidelines and ethics
board regulations.
Data Collection Regarding Clinical
Characteristics, Diagnostic Evaluation,
Neuroimaging and Clinical Status at the
Last Visit
Clinical data on the age at first clinical presentation, age at
diagnosis, period from the first symptoms to the last visit, birth
history, family history, nature of the first symptom, and organ
involvement were collected.
Laboratory test results, including serum lactic acid levels
and creatine kinase levels, were also obtained. The degree
of serum lactic acidosis was defined as mild, moderate, or
severe if the increase was <2, <3, or >3-fold higher than
the normal reference values, respectively. Biochemical enzyme
assay of the muscle tissue was also performed to evaluate
the mitochondrial respiratory chain (MRC) complex enzyme
activity. MRC complex enzyme defect was defined as a residual
enzyme activity of <10% the reference value. Muscle biopsies
were performed on the quadriceps muscle, and histologic
examinations were performed using a light microscope and an
electron microscope. Specific findings for mitochondrial diseases
under a light microscope were defined as the presence of ragged
red fibers (RRF) or abnormal staining. Abnormal mitochondrial
morphology was defined under the electron microscope as
pleoconia and megaconia. Data from genetic test of nuclear DNA
(nDNA) and mitochondrial DNA (mtDNA) was collected. Brain
MRI studies were also performed. The images used in this study
were taken at the time of diagnosis of LS.
The clinical severity of LS in the patients was defined
as: normal, ambulatory, and independent for daily activities;
mild, ambulatory, or independent for daily activities; moderate,
wheelchair-bound, or partially dependent for daily activities;
and severe, bedridden, totally dependent for daily activities, or
dead. At the last visit, data on whether they had undergone
tracheostomy, home vent use, O2 dependence, and enteral tube
feeding were also collected.
Subgroup Analysis by Age at Onset
A total of 110 patients were recruited in this study. Patients were
divided into two groups based on their age at LS onset. Age at
LS onset was divided into onset age of later than the second year
of life (late onset group) and onset age of before the second year
of life (early-onset group). Clinical features, laboratory findings,
and image findings were compared between the two groups.
Statistical Analysis
All analyses were conducted using the Statistical Package for
the Social Sciences (SPSS) version 22.0 (IBM Corp., Armonk,
NY, USA). Descriptive statistics were used, including the median
and range. Differences between subgroups were evaluated
using the Mann-Whitney U-test (Wilcoxon rank sum test)
and Fisher’s exacts test. P-values of <0.05 were considered
statistically significant.
RESULTS
Distribution of LS by Age at Onset
A total of 110 patients were diagnosed with LS. Among the
patients, 89 patients (80.9%) had an onset age of before 2 years
old, and 21 patents (19.1%) had an onset age of after 2 years old.
In 89 patients with a typical onset age of <2 years old, 17 patients
(15.5%) were between 1 and 2 years old and 72 patients (65.5%)
were under 1 year of age.
Patient Characteristics and Clinical
Features
Of the 110 patients who were diagnosed with LS, 51 (46.4%)
patients were male and 59 (53.6%) were female. The median
age at the first clinical presentation was 9 months (range 0–186
months). The median age at the diagnosis of LS was 25months
(range 3–244months). The time interval between the first clinical
presentation and the diagnosis of Leigh syndrome was 13 months
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(range 0–173 months). The time duration from LS diagnosis
to the last outpatient clinic visit was 109 months (range 4–290
months). Themedian duration of follow-up from symptom onset
to the last visit was 83 months (range 0–211 months). Regarding
birth history, a higher number of the infants were admitted in
the neonatal intensive care unit (13 patients, 11.8%). Of the
16 patients who had a family history, 13 patients (11.8%) had
mitochondrial disease history and 3 patients (2.7%) had a non-
specific neurological disease history. In the subgroup analysis, the
age at onset was divided into onset age of over 2 years old and
onset age of under 2 years, and the age at first clinical presentation
and the age at LS diagnosis were statistically significant (P< 0.05)
The presenting symptom at disease onset varied, with delayed
development (55 patients, 45.5%) as the most common, followed
by seizures (24 patients, 21.6%), motor weakness (11 patients,
9.5%), drowsiness (7 patients, 6.3%), ataxia (5 patients, 4.5%),
muscle atrophy (3 patients, 2.7%), and visual disturbance (2
patients, 1.8%). There were three significant differences in
presenting symptoms between the early-onset and late-onset
groups. Delayed development was significantly higher in the
early-onset group than in the late-onset group. Motor weakness
and ataxia were significantly higher in the late-onset group than
in the early-onset group. Among those 24 patients who showed
seizure as the presenting symptom at disease onset, we found that
11 patients (45.8%) had a focal seizure locus while 8 (33.3%) had
generalized seizure semiology. Complex partial seizure was the
most common type of focal seizure observed. As for generalized
seizure types, myoclonic seizure, tonic seizure, atonic seizure, and
tonic-clinic seizure were observed with relatively even prevalence
among patients. In addition, two patients showed partial seizure
with secondary generalization and three patients had unclassified
epileptic seizures. There was no significant difference in seizure
types between the early-onset and late-onset groups.
All the patients experienced involvement of the central
nervous system, followed by the muscular systems,
gastrointestinal and respiratory systems, and several organs.
Among the organ involvements, involvement of the muscular
systems, such as myopathy, creatine kinase level elevation, and
positive muscle biopsy findings, was significantly higher in the
late-onset group (Table 1).
Diagnostic Evaluation of Leigh Syndrome
The median serum lactate level at the time of diagnosis was
2.6 (range 0.9–20.7), and at the time of the last visit, it was 2.0
(range 0.6–14.0). Serum lactic acid level was increased in 64
patients (58.7%). Serum levels of lactic acid were found to be
mildly increased, moderately increased, and severely increased
in 26.6, 24.8, and 7.3% of patients, respectively. In most cases,
serum creatine kinase levels were normal both at the time of the
diagnosis and at the last visit.
Biochemical evaluation of MRC complex enzyme function
in the muscle tissue of 92 patients (no biochemical evaluation
results were found for 18 patients) showed defects in MRC
complex I and MRC complex IV in 53 patients (57.6%) and
34 patients (37.0%), respectively. Muscle biopsy, performed for
100 of the 110 patients, showed abnormal changes under a light
microscope in 25 patients (25%), including nonspecific findings
(3 patients), specific mitochondrial disease (22 patients), such
as RRF and abnormal staining. Abnormal findings under an
electron microscope were observed in 72 patients (72%); these
included pleoconia (37 patients) and megaconia (35 patients).
There was no significant difference between the subgroups
in lactic acidosis and elevation of serum creatine kinase
levels. In addition, no significant difference in MRC complex
enzyme assay and muscle biopsy findings was observed in the
subgroup analysis (Table 2).
In our study, genetic test of whole mtDNA and nDNA
was not performed in every patient. Out of 110 patients
with Leigh syndrome who met the clinical criteria, three
patients showed nDNA mutation and all had SURF1 gene
mutation. The mtDNA mutation was confirmed in 22 patients
(Supplementary Tables 1, 2).
MRI Findings in Leigh Syndrome
MRI of the brain revealed several abnormal findings in the
patients, including atrophy or abnormal signals in different areas
of the brain. Basal ganglia (104 patients, 94.5%) was the most
common abnormal MRI findings, followed by cerebral atrophy
(64 patients, 58.2%), and brainstem (45 patients, 40.9%), and
white matter signal abnormality (42 patients, 38.2%). There
was no significant difference between the subgroup in MRI
findings (Table 3).
Clinical Status at Last Visit
At the last outpatient clinic visit, 9 patients (8.2%) showed a
mild clinical severity (ambulatory and/or independent for daily
activities), 32 patients (29.1%) showed moderate clinical severity
(wheelchair-bound and/or partially dependent for daily activities,
able to express and understand direction), 58 patients (52.7%)
showed critical clinical severity (bedridden, total dependence
for daily activities), and the other patients were dead (11
patients, 10%). In addition, 27 patients underwent tracheostomy,
25 patients utilized home ventilator, 23 patients showed O2
dependence, and 38 patients were on enteral tube feeding.
By dividing the patients into subgroups according to onset
age, we found differences in clinical severity at the last visit to
be statistically significant. The clinical status of the early-onset
group was more severe (59.6%) than that of the late-onset group.
Therefore, the early- onset group had a poor prognosis compared
to the late-onset group. There was no significant difference
between the subgroups in previous tracheostomy, home vent use,
O2 dependence, and enteral tube feedings (Table 4).
DISCUSSION
LS is traditionally considered to be a disease of infancy and early
childhood that occurs before the age of 2 years (4, 15–17). More
than 50% of cases are observed in patients within one year of
age, usually six months old. Late-onset LS is rare worldwide (18).
Karin et al. described 25 patients with LS, and all 25 patients
had age onset younger than 2 years (16). Yang et al. described
65 patients with LS, and the age of LS onset in 59 patients was
<1 year (19). In our study, the onset age ranged from <1 to 187
months. There are many criteria to classify age of onset, and clear
criteria have not yet been established. Therefore, we divided early
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TABLE 1 | Clinical characteristics of Leigh syndrome.
Total Subgroup by age at onset P-value
Age ≤ 2yr (n = 89) Age > 2yr (n = 21)
Sex 0.228
Male 51 46.4 (%) 44 49.4 (%) 7 33.3 (%)
Female 59 53.6 (%) 45 50.6 (%) 4,514 66.7 (%)
*Age at the first clinical presentation (month) 9 0− 186 7 0–24 44 25–186 <0.001
*Age at the diagnosis of LS (month) 25 3− 244 21 3–185 60 25–244 <0.001
*The interval between the first clinical presentation and diagnosis of LS (month) 13 0− 173 13 0–153 12 0–173 0.698
*The duration from LS diagnosis to the last clinic visit (month) 109 4− 290 109 4–281 117 22–290 0.822
*The duration of follow-up from symptom onset to the last clinic visit (month) 83 0− 221 82 0–221 83 0–147 0.976
Birth history
Prematurity 4 3.6 (%) 4 4.5 (%) 0 0.0 (%) 0.423
Intrauterine growth retardation 5 4.5 (%) 5 5.6 (%) 0 0.0 (%) 0.126
Perinatal asphyxia 7 6.4 (%) 4 4.5 (%) 3 14.3 (%) 0.241
Neonatal intensive care unit history 13 11.8 (%) 12 13.5 (%) 1 4.8 (%) 0.339
Family history 16 14.5 (%) 11 12.4 (%) 5 23.8 (%) 0.406
Mitochondrial disease history 13 11.8 (%) 9 10.1 (%) 4 19.0 (%)
Non-specific neurological disease history 3 2.7 (%) 2 2.2 (%) 1 4.8 (%)
Presenting symptom at disease onset
Delayed development 55 49.5 (%) 50 56.2 (%) 5 23.8 (%) 0.008
Seizure 24 21.6 (%) 20 22.5 (%) 4 19.0 (%) 0.495
Motor weakness 11 9.9 (%) 6 6.7 (%) 5 23.8 (%) 0.019
Drowsiness 7 6.3 (%) 5 5.6 (%) 2 9.5 (%) 0.400
Ataxia 5 4.5 (%) 2 2.2 (%) 3 14.3 (%) 0.047
Muscle atrophy 3 2.7 (%) 3 3.4 (%) 0 0.0 (%) 0.526
Visual disturbance 2 1.8 (%) 1 1.1 (%) 1 4.8 (%) 0.347
Ear disorder 1 0.9 (%) 1 1.1 (%) 0 0.0 (%) 0.809
Behavior change 1 0.9 (%) 0 0.0 (%) 1 4.8 (%) 0.191
Ptosis 1 0.9 (%) 1 1.1 (%) 0 0.0 (%) 0.809
Organ involvement
Central nervous system 110 100 (%) 89 100.0 (%) 21 100.0 (%) –
Muscular 52 47.3 (%) 38 42.7 (%) 14 66.7 (%) 0.048
Gastrointestinal 41 37.3 (%) 35 39.3 (%) 6 28.6 (%) 0.359
Respiratory 33 30.0 (%) 29 32.6 (%) 4 19.0 (%) 0.171
Ophthalmic 17 15.5 (%) 15 16.9 (%) 2 9.5 (%) 0.323
Cardiologic 9 8.2 (%) 9 10.1 (%) 0 0.0 (%) 0.137
Renal 8 7.3 (%) 8 9.0 (%) 0 0.0 (%) 0.172
Auditory 6 5.5 (%) 4 4.5 (%) 2 9.5 (%) 0.322
Hematologic 1 0.9 (%) 0 0.0 (%) 0 0.0 (%) –
Endocrinologic 1 0.9 (%) 1 1.1 (%) 0 0.0 (%) 0.809
*Continuous variables are descripted by medians and ranges.
Other variables are descripted by number of patients and percentage (%) in each group.
onset and late onset based on age of 2 years. Under 2 years old
age onset were dominant in 80.9%.
According to previous reports, typical signs and symptoms
may appear in late-onset LS (20). In late-onset Leigh syndrome,
there was intellectual decline and vertical gaze paralysis,
headache, memory loss, and visual hallucinations (21, 22). They
were based on a small number of case reports. Generally,
Leigh syndrome in adulthood is rare (20). Our results showed
that delayed development, motor weakness, and ataxia among
the presenting symptoms at disease onset were statistically
significant. However, the time interval from the first clinical
presentation to the diagnosis of LS, follow-up duration, birth
history, family history, and organ involvement were not
statistically significant. Therefore, Leigh syndrome should be
considered when symptoms related to gross motor function
such as delayed development, motor weakness, and ataxia
are observed. In particular, these symptoms can be classified
according to the age of onset. There is a frequency of difference
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TABLE 2 | Diagnostic evaluation of Leigh syndrome.
Total Subgroup by age at onset P-value
Age ≤ 2yr (n = 89) Age > 2yr (n = 21)
Lactate (mmol/L)
*At the time of diagnosis 2.6 0.9–20.7 2.6 0.9–20.7 2.4 1.2–7.0 0.563
*Last visit 2.0 0.6–14.0 2.1 0.8–14.0 1.9 0.6–4.3 0.086
Lactate/pyruvate ratio
*At the time of diagnosis 16.8 4.8–260.0 17.0 4.8–260.0 15.7 7.1–40.0 0.396
*Last visit 16.1 4.8–176.9 16.8 4.8–68.6 15.7 5.0–176.9 0.142
Lactic acidosis (n = 109) (n = 89) (n = 20)
Normal 45 41.3 (%) 36 40.4 (%) 9 45.0 (%)
Mild increased (≥2-fold) 29 26.6 (%) 22 24.7 (%) 7 35.0 (%) 0.193
Moderate increased (≥3-fold) 27 24.8 (%) 24 27.0 (%) 3 15.0 (%)
Severe increased (≥4-fold) 8 7.3 (%) 7 7.9 (%) 1 5.0 (%)
Creatine kinase (mmol/L)
*At the time of diagnosis 101 15− 1, 257 99 15–1,257 109 22–409 0.948
Normal 75 68.2 (%) 58 65.2 (%) 56 62.9 (%)
Mild increased (<2-fold) 29 26.4 (%) 26 29.2 (%) 25 28.1 (%) 0.995
Severe increased (≥2-fold) 6 5.5 (%) 5 5.6 (%) 8 9.0 (%)
*Last visit 113 7–873 117 7–873 105 27–595 0.550
Normal 69 62.7 (%) 17 81.0 (%) 13 61.9 (%)
Mild increased (<2-fold) 31 28.2 (%) 3 14.3 (%) 6 28.6 (%) 0.353
Severe increased (≥2-fold) 10 9.1 (%) 1 4.8 (%) 2 9.5 (%)
Plasma amino acid (n = 88)
*Alanine 389 102–1,028 390 158–1,028 378 102–652 0.303
Normal 52 59.1 (%) 41 57.7 (%) 11 64.7 (%)
Mild increased (≥2-fold) 31 35.2 (%) 25 35.2 (%) 6 35.3 (%) 0.721
Severe increased (≥4-fold) 5 5.7 (%) 5 7.0 (%) 0 0.0 (%)
*Glycine 213 98–8,010 208 108–8,010 217 98–355 0.763
Normal 87 97.8 (%) 70 97.2 (%) 17 100.0 (%)
Abnormal (≥2-fold) 2 2.2 (%) 2 2.8 (%) 0 0.0 (%) 0.785
*Proline 173 0–518 176 0–518 133 0–232 0.021
Normal 82 92.1 (%) 65 90.3 (%) 17 100.0 (%)
Abnormal (≥2-fold) 7 7.9 (%) 7 9.7 (%) 0 0.0 (%) 0.408
*Threonine 116 38–762 117 38–762 101 43–177 0.031
Normal 94 85.5 (%) 78 92.9 (%) 16 94.1 (%) 0.128
Abnormal (≥2-fold) 7 6.4 (%) 6 7.1 (%) 1 5.9 (%)
Urine organic acid (n = 71) (n = 56) (n = 15) 0.819
Abnormal finding 36 50.7 (%) 28 50 (%) 8 53.3 (%)
MRC complex enzyme assay (n = 92) (n = 75) (n = 17) 0.888
MRC complex I defect 53 57.6 (%) 42 47.2 (%) 11 64.7 (%)
MRC complex IV defect 34 37.0 (%) 29 32.6 (%) 5 29.4 (%)
Muscle biopsy obtained (n = 80) (n = 20)
Light microscopic changes (+) 0.296
Specific findings for mitochondrial diseases 22 22 (%) 15 18.8 (%) 7 35.0 (%)
Non-specific findings 3 3 (%) 3 3.8 (%) 0 0.0 (%)
Electron microscopic changes (+)
Pleoconia 37 37 (%) 26 32.5 (%) 11 55.0 (%) 0.123
Megaconia 35 35 (%) 25 31.3 (%) 10 50.0 (%) 0.207
*Continuous variables are descripted by medians and ranges.
Other variables are descripted by number of patients and percentage (%) in each group.
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TABLE 3 | Magnetic resonance imaging findings.
Total Subgroup by age at onset P-value
Age ≤ 2yr (n = 89) Age > 2yr (n = 21)
Basal ganglia 104 94.5 (%) 84 94.4 (%) 20 95.2 (%) 0.678
Thalamus 38 34.5 (%) 33 37.1 (%) 5 23.8 (%) 0.071
Brainstem 45 40.9 (%)
Midbrain 44 40.0 (%) 35 39.3 (%) 9 42.9 (%) 0.766
Pons 27 24.5 (%) 22 24.7 (%) 5 23.8 (%) 0.931
Medulla 30 27.3 (%) 23 25.8 (%) 7 33.3 (%) 0.488
Number of brain stem parts involved 0.067
0 62 56.4 (%) 51 57.3 (%) 11 52.4 (%)
1 17 15.5 (%) 15 16.9 (%) 2 9.5 (%)
2 10 9.1 (%) 5 5.6 (%) 5 23.8 (%)
3 21 19.1 (%) 18 20.2 (%) 3 14.3 (%)
Cerebellum 41 37.3 (%) 35 39.3 (%) 6 28.6 (%) 0.359
Cerebral atrophy 64 58.2 (%) 0.332
Mild 49 44.5 (%) 40 44.9 (%) 9 42.9 (%)
Severe 15 13.6(%) 14 15.7 (%) 1 4.8 (%)
Cortex signal abnormality 33 30.0 (%) 28 31.5 (%) 5 23.8 (%) 0.491
White matter signal abnormality 42 38.2 (%) 0.524
Mild 40 36.4 (%) 34 38.2 (%) 6 28.6 (%)
Severe 2 1.82 (%) 2 2.2 (%) 0 0.0 (%)
TABLE 4 | Clinical status at the last visit.
Total Subgroup by age at onset P-value
Age ≤ 2yr (n = 89) Age > 2yr (n = 21)
Clinical severity 0.004
Mild 9 8.2 (%) 5 5.6 (%) 4 19.0 (%)
Moderate 32 29.1 (%) 21 23.6 (%) 11 52.4 (%)
Severe 58 52.7 (%) 53 59.6 (%) 5 23.8 (%)
Dead 11 10.0 (%) 10 11.2 (%) 1 4.8 (%)
Regression 73 66.4 (%) 59 66.3 (%) 14 66.7 (%) 0.974
Tracheostomy 0.177
Yes 27 24.5 (%) 24 26.9 (%) 3 14.3 (%)
No 83 75.5 (%) 65 73.0 (%) 18 85.7 (%)
Home ventilator use 0.236
Yes 25 22.7 (%) 22 24.7 (%) 3 14.3 (%)
No 85 77.3 (%) 67 75.3 (%) 18 85.7 (%)
O2 dependence 0.453
Continuous 6 5.5 (%) 6 6.7 (%) 0 0.0 (%)
Temporary 17 15.5 (%) 14 15.7 (%) 3 14.3 (%)
No 87 79.1 (%) 69 77.5 (%) 18 85.7 (%)
Enteral tube feeding 0.155
Temporary tube feeding 15 38.2 (%) 13 14.6 (%) 2 9.5 (%)
Continuous tube feeding 4 38.2 (%) 4 4.5 (%) 0 0.0 (%)
Gastrostomy feeding 19 17.3 (%) 18 20.2 (%) 1 4.8 (%)
between the specific symptoms in early onset and late onset
patients. Delayed development is important in cases of early
age of onset, and motor weakness or ataxia is important in
cases of late age of onset. Consequently, mitochondrial disease
should be suspected if the initial symptoms such as delayed
development, motor weakness, and ataxia and regression are
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detected. Seizure and epilepsy in children with early-onset
mitochondrial disease may be a presenting or a prominent
symptom in a multisystemic clinical presentation. However, a
higher prevalence of Leigh syndrome was detected in non-
epileptic patients (23, 24). Though seizures took the place of
the second most common presenting symptom at disease onset
in our study, there was no case of severe condition as status
epilepticus. The most frequent causes of mitochondrial status
epilepticus are known asmitochondrial encephalomyopathy with
lactic acidosis and stroke-like episodes (MELAS) and myoclonus
epilepsy with ragged-red fibers (MERRF) (25).
LS is typically characterized by the involvement of the
brainstem and/or basal ganglia (4, 26). Other areas of frequent
involvement include the thalamus, cerebellum, and spinal cord
(7, 14). Similar to previous studies, brainstem, basal ganglia, and
thalamus involvement were more common in our results, with
basal ganglia involvement being the most common. There was no
significant difference between MRI findings according to onset
age. Therefore, it is clinically meaningful to compare the interval
changes in neuroimaging by individual follow up rather than
MRI findings according to onset age. Although the consensus
on when to repeat brain MRI in LS has not reached a definite
conclusion yet, it is important to follow up MRI findings at
regular intervals to compare changes.
The disease course is associated with episodic
neurodegeneration, often ending with death until the age
of 5 years (27). However, according to our results, the median
time from the first symptom onset to the last visit was 83 months,
which is longer than what was observed in previous studies.
No causative treatment is available for Leigh disease because
no treatment can reverse the sustained damage. Thus, the goal
of each treatment are to reduce the expected deterioration rate
and to alleviate symptoms such as respiratory disturbances
and tube feeding. The reason for the prolongation of patient’s
survival period to 5 years or more is considered to be due to
multidisciplinary treatment and supportive care, including serial
monitoring and the use of various medication at LS diagnosis.
The type of medication used supplements RC components
like coenzyme Q, administers artificial electron acceptors like
vitamin C and K, and administers metabolites and cofactors like
carnitine, thiamin, and riboflavin (28). The clinical severity of LS
in the early-onset group was worse than in the late onset group,
and in the early-onset group, the proportion of patients with
critical clinical severity or those who died was 70.8%, whereas
in the late-onset group, 71.4% of patients had mild or moderate
clinical severity. A difference in prognosis was shown according
to onset age. Although there are reports of both early and
late-onset LS, there is no comparative study of their prognosis.
Therefore, it is necessary to compare their prognosis according
to the age at onset.
Our study is a retrospective study with limited genetic
diagnosis. A study conducted using retrospective design generally
includes patients recruited over a long period making it
practically impossible to perform genetic assessment in all
patients and under the same condition. In our study, genetic
tests for whole nDNA and mtDNA were not performed in all
patients. Therefore, the number of patients with a confirmed
mutation was too small to make statistically meaningful analysis.
A study based on a large sample with full genetic assessment
would be very helpful. Even a smaller cohort with genetic
confirmation could be quite significant. However, the rarity
of the disease makes it hard to find a study population big
enough to provide generalized interpretations. That is also
the reason for why studies on rare diseases are scarce when
compared with those on common diseases. Despite the limitation
of genetic diagnosis, standards of clinical diagnosis criteria,
biochemical assay, and muscle pathology were applied very
strictly in this study to make definite diagnosis. This was a
large-scale study involving more than 100 patients in a single
institution that meets previously established diagnostic criteria.
Because LS is a rare disease, performing a prospective study
has limitations because only a few cases will be available for
research. However, we noted that early-onset and late-onset LS
are similar in clinical phenotype and MRI finding, but their
prognosis is quite different. In this study, we analyzed clinical
phenotypes according to onset age. However, long-term studies
involving a larger patient cohort with evaluation of the genotype
of patients in each group could provide further prediction of
the prognosis in LS. Individualized treatment is possible if we
recognize the differences according to the onset age of LS.
Therefore, the onset age of LS will ultimately be helpful for
personalized treatment.
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